Orphazyme A/S ORPHY OTC

Other OTC • Healthcare • Biotechnology • DK • USD

SharesGrow Score

51/100

1/4 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Orphazyme A/S (ORPHY) .

Criteria proven by this page:

VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.

Overall SharesGrow Score: 47/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

51/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

MOAT

46/100

→ Income

GROWTH

58/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — ORPHY

Valuation Multiples

P/E (TTM)0.0

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio0.00

P/S Ratio0.00

EV/EBITDA0.0

Per Share Data

EPS (TTM)$-0.74

Book Value / Share$0.00

Revenue / Share$0.00

FCF / Share$0.00

Yields & Fair Value

Earnings YieldN/A

Dividend Yield0.00%

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2015	$-4.66	$0.00	$-47.71M	-
2016	$-5.65	$0.00	$-57.94M	-
2017	$-10.43	$0.00	$-126.2M	-
2018	$-11.47	$0.00	$-229.6M	-
2019	$-16.87	$0.00	$-337.5M	-
2020	$-22.32	$0.00	$-633.25M	-
2021	$-17.94	$36.19M	$-626.54M	-1731.1%
2022	$-3.14	$0.00	$-110.59M	-
2023	$-0.74	$0.00	$-26.05M	-